Posts

Vaxcyte shares surge after positive Phase 3 vaccine results

on
On October 5, 2026, Vaxcyte said its experimental 31-valent pneumococcal vaccine, VAX-31, met the main immune-response goals in the pivotal adult Phase 3 OPUS-1 trial. The 4,047-person trial found VAX-31’s immune responses were non-inferior to comparator vaccines for the serotypes assessed against Pfizer’s Prevnar 20 and Merck’s Capvaxive. The company also reported stronger responses for several additional serotypes. Safety and tolerability were described as comparable to the licensed vaccines. Vaxcyte shares jumped roughly 50–57% in early trading following the announcement, according to reports. The result is an important step, not an approval: VAX-31 remains investigational. Vaxcyte expects results from two other adult Phase 3 trials, OPUS-2 and OPUS-3, in the first half of 2027, and has said it plans to seek FDA approval through a Biologics License Application. Sources: Vaxcyte shares surge as pneumococcal vaccine succeeds ... Vaxcyte's stock up after pneumococcal ...

FDA extends review of Novo’s hemophilia A drug over factory remediation

on

Genentech licenses Alector’s preclinical Parkinson’s candidate for $100 million upfront

on

CSL and Alentis strike up to US$1.6 billion drug-development deal

on

Recent pharma deals: AstraZeneca backs ivonescimab

on

Bayer plans $2.2 billion Ohio pharmaceutical manufacturing campus

on

Possible match: NTx raises $47.5M for RNA manufacturing

on

Asia pharma deal roundup: AZ backs ivonescimab, Novo licenses Hengrui’s GLP-1/GIP drug, Merck targets KRAS

on

AstraZeneca backs Summit with $2 billion stake and cancer-drug collaboration

on

Pharma deals spotlight China’s growing role in drug pipelines

on

Pharma deal headlines: AstraZeneca backs ivonescimab, Novo licenses Hengrui’s obesity candidate

on

Novartis strikes potential $7.8 billion Abogen deal for in vivo autoimmune therapy

on

Regeneron plans obesity-drug and cholesterol-therapy combination

on